<DOC>
	<DOCNO>NCT01059526</DOCNO>
	<brief_summary>The objective study evaluate formation antibody , occurence allergic reaction , risk hypercoagulability hypocoagulability patient treat KALBITOR ( ecallantide ) .</brief_summary>
	<brief_title>Observational Safety Study KALBITOR ( Ecallantide ) Treatment Acute Attacks Hereditary Angioedema</brief_title>
	<detailed_description>The objective study evaluate immunogenicity hypersensitivity upon exposure KALBITOR , particular : 1 . Determine rate anaphylaxis Type I hypersensitivity reaction upon exposure KALBITOR . 2 . Determine rate seroconversion anti-ecallantide antibody upon exposure KALBITOR . 3 . Determine rate adverse event relate disordered coagulation ( hypercoagulability hypocoagulability ) upon exposure KALBITOR .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Patients indicate per approve product label KALBITOR Patient guardian able understand sign inform consent form Patient willing able undergo skin test procedure screening ( baseline ) Patient contraindicate per approve product label KALBITOR Patient confirm pregnancy active breastfeeding Any condition , opinion Investigator , may compromise safety compliance patient would preclude patient successful completion study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HAE</keyword>
</DOC>